Navigation Links
OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
Date:7/18/2011

HONG KONG, July 18, 2011 /PRNewswire/ -- Data from high-risk patients requiring early discontinuation of dual antiplatelet therapy (DAPT) due to nondeferrable, non-cardiac surgery show good short- and long-term clinical and safety outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online on the journal Minerva Cardioangiologica's website.

In the single-center study, patients treated with the Genous endothelial progenitor cell (EPC) capture stent discontinued DAPT between 21 and 30 days post-procedure and underwent non-cardiac surgical intervention within 60 days of percutaneous coronary intervention (PCI). Despite the shortened period of DAPT administration, there were no cases of stent thrombosis (ST) observed in patients treated with Genous.  Additionally, no cases of perioperative major adverse cardiac events (MACE) were detected. After a mean follow-up of 15.4+/-10.3 months, two cases of cardiac death were reported, with no ischemia-driven target lesion revascularization (TLR) observed.

"Patients in need of revascularization and subsequent non-cardiac surgery are a significant management challenge due to their increased risk for major adverse cardiovascular events related to stent thrombosis and intra-operative bleeding," said Paolo Scacciatella, M.D., of the Department of Cardiovascular and Thoracic Diseases, S. Giovanni Battista University Hospital, Turin, Italy, and lead author of the publication. "The results from this study confirm the feasibility and safety of the Genous Stent in patients requiring early discontinuation of DAPT as a result of nondeferrable surgical intervention. Given the lack of stent thrombosis over the long term in patients with high clinical and angiographic risk, the Genous Stent represents an attractive alternative to bare metal and drug eluting stents f
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Confirms that OrbusNeichs Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
2. OrbusNeichs Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011
3. Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeichs Genous™ Stent in Diabetic Patients
4. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
5. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
6. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
7. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
8. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
9. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
10. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
11. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... 2007 /PRNewswire/ -- Mersana, a,cancer therapeutics company, announced ... product candidate, XMT-1001, will,be presented in two posters ... of Cancer Research (AACR) taking place April,14-18th in ... can be,viewed online at the AACR website at ...
... 13, 2007 - Biogen Idec Inc.,(NASDAQ: BIIB) ... the,Academy of Managed Care Pharmacy's (AMCP) 2007 ... a cost-effective therapy in,multiple sclerosis (MS) when ... comprehensive analysis of medical and pharmacy,costs, the ...
Cached Medicine Technology:Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 3
(Date:12/26/2014)... 26, 2014 It is said that nothing ... Today, UWDress.com, the famous wedding dress supplier, shows its ... site-wide cocktail gown promotion. , UWDress.com’s navy cocktail gowns ... they come in high fashion styles. Simple dresses in bright ... the occasion; they are specially designed for those who want ...
(Date:12/26/2014)... Plugin and template developers from Pixel Film Studios ... Cut Pro X. , “TransPack Volume 5 gives users the ... an industry professional look” Said Christina Austin, CEO of Pixel ... 5, a new level of professionalism will become the standard.” ... Final Cut Pro X transitions featuring organic animations. Choose from ...
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... Nov. 28 Anthem Blue Cross and Blue,Shield in ... than,$185,000 to support 212 not-for-profit organizations as part of ... and Blue Shield,Foundation will match 50 percent of associate ... "Every day our associates ...
... vaccination for parents of new babies and other household members ... form of whooping cough in young infants, say a group ... , Whooping cough (pertussis) is a distressing infectious disease which ... usually given to infants at two to four months of ...
... Eliminating sugary beverages did not affect overall consumption, study ... new study suggests that cutting sodas and other sugar-sweetened ... on teens, overall consumption of the beverages. , ... contributor to increasing rates of childhood obesity in the ...
... vs. local delivery , , WEDNESDAY, Nov. 26 (HealthDay News) -- ... the same for patients who have general or local anesthesia, ... the findings, they say that doctors and patients should decide ... Blocked neck arteries increase the risk of stroke, and a ...
... LONDON, Nov. 27 To coincide with Staying Alive,s ... International has,announced the appointment of Travis McCoy, lead vocalist ... Foundation,s new 2009 Ambassador. , ... Kelly Rowland (Ambassador,since 2008), Beyonce, Mary J Blige, Justin ...
... used to determine which patients will benefit, researchers say , , ... tell doctors whether people with a certain type of non-Hodgkin ... to a new study. , Three different signatures ... biological activity of a gene -- have been identified in ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in Maine Associates Pledge More Than $277,500 to Community Organizations 2Health News:Parents of new babies should be considered for a whooping cough booster, say experts 2Health News:School Soda Ban Has Limited Effect 2Health News:Anesthesia Type Won't Influence Neck Artery Surgery Outcomes 2Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 2Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 3Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 4Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 5Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 6Health News:Genes May Predict Lymphoma Treatment Outcome 2
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
... The Brasseler USA™ MicroLine™ Small Bone ... of operation while performing under the ... powered system developed for small bone ... Drill, Sagittal Saw (Extended Length Available), ...
... Drill, with hand throttle, 30,000 ... Built-in medium bur guard included, ... bur guards are also available. ... hand throttle (#1940) for use ...
... Electric Micro Drill, without hand ... of torque. Built-in medium bur ... extra-long (#1100-006) bur guards are ... with foot throttle (#6401-000), can ...
Medicine Products: